Cite
HARVARD Citation
Yacyshyn, B. et al. (2021). Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease. Crohn's & colitis 360. 3 (1), p. . [Online].